232 related articles for article (PubMed ID: 36622326)
1. Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia.
Irani YD; Kok CH; Clarson J; Shanmuganathan N; Branford S; Yeung DT; Ross DM; Hughes TP; Yong ASM
Blood Adv; 2023 Jun; 7(11):2364-2374. PubMed ID: 36622326
[TBL] [Abstract][Full Text] [Related]
2. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.
Hughes A; Clarson J; Tang C; Vidovic L; White DL; Hughes TP; Yong AS
Blood; 2017 Mar; 129(9):1166-1176. PubMed ID: 28049640
[TBL] [Abstract][Full Text] [Related]
3. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
[TBL] [Abstract][Full Text] [Related]
4. Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment.
Kong J; Qin YZ; Zhao XS; Hou Y; Liu KY; Huang XJ; Jiang H
Ann Hematol; 2021 Oct; 100(10):2557-2566. PubMed ID: 34278524
[TBL] [Abstract][Full Text] [Related]
5. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
[TBL] [Abstract][Full Text] [Related]
6. Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.
Schütz C; Inselmann S; Saussele S; Dietz CT; Mu Ller MC; Eigendorff E; Brendel CA; Metzelder SK; Bru Mmendorf TH; Waller C; Dengler J; Goebeler ME; Herbst R; Freunek G; Hanzel S; Illmer T; Wang Y; Lange T; Finkernagel F; Hehlmann R; Huber M; Neubauer A; Hochhaus A; Guilhot J; Xavier Mahon F; Pfirrmann M; Burchert A
Leukemia; 2017 Apr; 31(4):829-836. PubMed ID: 28074067
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells.
Irani YD; Hughes A; Clarson J; Kok CH; Shanmuganathan N; White DL; Yeung DT; Ross DM; Hughes TP; Yong ASM
Br J Haematol; 2020 Nov; 191(3):433-441. PubMed ID: 32352166
[TBL] [Abstract][Full Text] [Related]
8.
Ureshino H; Shindo T; Tanaka H; Saji H; Kimura S
Mol Cancer Ther; 2021 Jan; 20(1):142-149. PubMed ID: 33082274
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis.
Solorzano-Ibarra F; Alejandre-Gonzalez AG; Ortiz-Lazareno PC; Bastidas-Ramirez BE; Zepeda-Moreno A; Tellez-Bañuelos MC; Banu N; Carrillo-Garibaldi OJ; Chavira-Alvarado A; Bueno-Topete MR; Del Toro-Arreola S; Haramati J
Clin Exp Immunol; 2021 Apr; 204(1):78-95. PubMed ID: 33306195
[TBL] [Abstract][Full Text] [Related]
10. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts.
Poh SL; Linn YC
Cancer Immunol Immunother; 2016 May; 65(5):525-36. PubMed ID: 26961084
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of the immune pattern of T cell subsets in chronic myeloid leukemia before and after TKI treatment.
Yao D; Lai J; Lu Y; Zhong J; Zha X; Huang X; Liu L; Zeng X; Chen S; Weng J; Du X; Li Y; Xu L
Front Immunol; 2023; 14():1078118. PubMed ID: 36742315
[TBL] [Abstract][Full Text] [Related]
13. Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment-free remission.
Kumagai T; Nakaseko C; Nishiwaki K; Yoshida C; Ohashi K; Takezako N; Takano H; Kouzai Y; Murase T; Matsue K; Morita S; Sakamoto J; Wakita H; Sakamaki H; Inokuchi K;
Cancer Sci; 2020 Aug; 111(8):2923-2934. PubMed ID: 32614159
[TBL] [Abstract][Full Text] [Related]
14. The prognostic role of NKG2A expression for patients with chronic myeloid leukemia after treatment discontinuation.
Xu Z; Yin J; Sun Q; Hu J; Hong M; Qian S; Liu W
Leuk Lymphoma; 2022 Nov; 63(11):2616-2626. PubMed ID: 35758278
[TBL] [Abstract][Full Text] [Related]
15. Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation.
Huuhtanen J; Adnan-Awad S; Theodoropoulos J; Forstén S; Warfvinge R; Dufva O; Bouhlal J; Dhapola P; Duàn H; Laajala E; Kasanen T; Klievink J; Ilander M; Jaatinen T; Olsson-Strömberg U; Hjorth-Hansen H; Burchert A; Karlsson G; Kreutzman A; Lähdesmäki H; Mustjoki S
Leukemia; 2024 Jan; 38(1):109-125. PubMed ID: 37919606
[TBL] [Abstract][Full Text] [Related]
16. Elevated frequencies of CD8 T cells expressing PD-1, CTLA-4 and Tim-3 within tumour from perineural squamous cell carcinoma patients.
Linedale R; Schmidt C; King BT; Ganko AG; Simpson F; Panizza BJ; Leggatt GR
PLoS One; 2017; 12(4):e0175755. PubMed ID: 28423034
[TBL] [Abstract][Full Text] [Related]
17. Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape.
Hsieh YC; Kirschner K; Copland M
Leukemia; 2021 May; 35(5):1229-1242. PubMed ID: 33833387
[TBL] [Abstract][Full Text] [Related]
18. Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
Cayssials E; Torregrosa-Diaz J; Gallego-Hernanz P; Tartarin F; Systchenko T; Maillard N; Desmier D; Machet A; Fleck E; Corby A; Motard C; Denis G; Herbelin A; Gombert JM; Roy L; Ragot S; Leleu X; Guilhot F; Chomel JC
Cancer; 2020 Aug; 126(15):3438-3447. PubMed ID: 32459375
[TBL] [Abstract][Full Text] [Related]
19. [Chronic myeloid leukemia and NK cell immunity].
Ureshino H; Shindo T; Tanaka H; Kimura S
Rinsho Ketsueki; 2017; 58(4):381-388. PubMed ID: 28484170
[TBL] [Abstract][Full Text] [Related]
20. [Tyrosine kinase inhibitor therapy discontinuation for chronic myelogenous leukemia to achieve clinical cure: current status and future perspectives].
Kumagai T
Rinsho Ketsueki; 2018; 59(10):2094-2103. PubMed ID: 30305514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]